im gonna be excited and want to share these news with you but dont be negative Product 3/7/2024
The user is excited about an upcoming update for GT20029, expected in March. They express frustration with the negativity on Reddit.
View this post in the Community →
Similar Community Posts Join
5 / 348 resultscommunity Anyone excited for CosmeRNA coming this month?
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.
community Please explain this Minoxidil phenomena
The post discusses the difference in effects of Minoxidil (Min) on scalp and facial hair. The user questions why Min-induced hair growth on the scalp is temporary, while facial hair growth seems permanent, even after stopping Min. They propose theories, including different Min mechanisms on body and facial hair, the role of DHT, and the possibility of not achieving fully terminal hair. The responses include personal experiences and theories about Min's effects on hair growth.
community Future hope ? What do you guys predict ? clascoterone, pyrilutamide, gt20029 etc.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
community Dutasteride 1 year regression. Depressing. (With pictures for proof)
A user shared their experience of hair loss progression after one year on dutasteride, expressing disappointment with no improvement and considering other treatments like RU58841. Other users offered mixed responses, some seeing no change, others suggesting the hair loss might have been worse without treatment, and discussing the role of testosterone and DHT in hair loss.
community Kintor has announced the results for their human Phase I trials of GT20029
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
Related Research
6 / 11 results
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Updates in Treatment for Androgenetic Alopecia
New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.
research The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
research Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
GT20029 helps regrow hair in men with hair loss and is well-tolerated.
research Methodological Considerations in Evaluating Early Clinical Outcomes of GT20029 for Androgenetic Alopecia
GT20029 showed some hair growth improvement, but longer studies are needed for better results.